🔗 Share this article

As America continues making sweeping revisions to its vaccination schedules, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccines throughout the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities planned to announce sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of alignment with many the global community with no evidence for benefit. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to run the center this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain pediatric shot schedules in the US to become more like Denmark's approach, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – usually the responsibility of Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Qualifications

Høeg has no obvious background in medication creation, approval processes or administrative roles, which has been standard for past leaders of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former directors of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who led the center have had.”

This division has an enormous workload at the agency, the former commissioner stated.

“The public just focuses on the new drug program, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and all of those have to be supervised,” Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the job, which oversees more than 5,000 staff members. “It is a huge management job, if you do it right,” she added.

Response and Contentious Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this selection represents greater collaboration among agency officials on vaccines, a spokesperson responded that the “concerns are based on inaccurate premises”.

“Her experience is consistent with the functions of her job,” the representative stated, noting the time Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a contentious expedited drug-approval program that apparently worried her former heads. “How are these therapies being chosen for this fast-track system? Who takes the choices?” Howard said. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the agency looks to be trending towards more relaxed regulations of all drugs, except for shots.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, track record, Howard said. She authored a analysis using unverified public submissions to assess the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the incoming government featured altering guidelines for new vaccines and discontinuing “unnecessary” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has according to sources proposed excluding teenage boys from receiving Covid vaccines.

“She’s an complete true believer who starts off with her conclusions and reverse-engineers to accommodate the evidence in a very deceptive, dishonest manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg joined other dissenters, {like|